6606 POSTER

Three drug regimen in SCLC-ED patients: a phase II study

K. Syrigos, K. Pantazopoulos, A. Charpidou, I. Gkiozos, I. Tzannou, C. Alamara, K. Dilana, E. Kotteas, N. Katirtzoglou. *Medical School University of Athens, 3rd Internal Medicine, Athens, Greece*

Background: Small cell lung cancer (SCLC) is an aggressive malignancy. The prognosis for the patients is very poor with metastases often present at the time of diagnosis. Despite the initial chemo-sensitivity the majority of the patients will relapse and die of their disease. Patient with Extensive Disease (ED) have a disappointing survival of 8−12 weeks without chemotherapy and 8−11 months after proper treatment. Irinotecan, a topoisomerase I inhibitor, has been reported as an active new agent in SCLC. In combination with cisplatin, it has showed superiority in response rates and progression free survival over the standard regimen of cisplatin and etoposide. We conducted a phase II study in order to evaluate the efficacy and safety of Carboplatin, Irinotecan and Etoposide (CIE) combination in extensive-disease SCLC (ED-SCLC)
Patients and Methods: Forty six chemo-naive patients with ED-SCLC and PS 0−2 were enrolled. Forty of them were men and 6 women. All of them were smokers and the median age was 59.6 years. We administered carboplatin AUC 5 on day 1, irinotecan 120/m2 on day 2 and etoposide 75 mg/m^2 on days 1, 2, 3 in a 21 days repeated cycles. The treatment was continued for up to 6 cycles. Response assessments were performed after cycles 3 and 6 and every 2 months subsequently. The patients were evaluated for response, survival and toxicity. Clinical (as site of metastasis) and laboratory (such as LDH) parameters were tested as prognostic factors for survival.
Results: Two hundred and two cycles were administered with an average of 4.5 cycle per patient. Overall response rate was 52.2% (partial and complete), mean overall survival was 16.3 months (CI: 95%: 13.0−19.7) and there was a 1 year survival rate of 43.47%. Patients with brain metastasis had worse prognosis (P:0.004).
The three drug regimen was well tolerated. Only 1 patient had diarrhea grade II, 6 had grade III/IV and 1 patient was referred with abdominal pain. One was presented with fatal thrombocytopenia while two toxic deaths were reported. Nine patients (19.5%) had neutropenia grade III/IV, without being fatal, and 3 were presented with grade III anemia which need blood transfusions.
Conclusion: CIE regimen is effective and well tolerated for the treatment of the poor prognosis group of ED-SCLC patients

6607 POSTER

Preliminary findings of a phase I dose-escalation study of sunitinib in combination with gemcitabine plus cisplatin in advanced non-small cell lung cancer (NSCLC)

M. Reck[1], N. Frickhofen[2], U. Gatzemeier[1], H.G. Fuhr[2], S. Lanzalone[3], E. Wang[4], R. Chao[4], E. Felip[5]. *[1]Hospital Grosshansdorf, Department of Thoracic Oncology, Grosshansdorf, Germany; [2]HSK, Dr Horst Schmidt Klinik, Wiesbaden, Germany; [3]Pfizer Italia srl, Via Lorenteggio, Milan, Italy; [4]Pfizer Inc, Global Research and Development, La Jolla, USA; [5]Vall d'Hebron University Hospital, Oncology Department, Barcelona, Spain*

Background: Sunitinib malate (SUTENT®; SU), is an oral, multitargeted tyrosine kinase inhibitor of VEGFRs, PDGFRs KIT, RET and FLT3, and is approved internationally for the treatment of advanced RCC and imatinib-resistant/-intolerant GIST. VEGFRs, which play a key role in angiogenesis, are overexpressed in NSCLC, and single-agent antitumor activity of sunitinib in advanced NSCLC patients (pts) has previously been demonstrated (11.1% response rate; Socinski, ESMO 2006). Preliminary findings of a phase I, dose-escalation study of SU in combination with gemcitabine (G) and cisplatin (C) are reported here.
Patients and Methods: Eligible pts have untreated, stage IIIB/IV NSCLC not amenable to curative treatment, ECOG PS $\leqslant$ 1 and adequate organ function. Pts receive SU (37.5 or 50 mg/d) on a repeated 2/1 schedule (2 wks on, 1 wk off treatment), plus G (1000 or 1250 mg/m^2 iv on days 1 and 8 of a 21 day cycle) and C (80 mg/m^2 iv on day 1 of each cycle). Evaluation of a continuous dosing (CD) schedule of SU is also planned. SU doses are escalated in serial pt cohorts to determine the primary endpoint – the maximum tolerated dose of SU for both dose schedules in this combination regimen. Secondary endpoints include the antitumor efficacy and pharmacokinetics of SU plus G and C.
Results: As of April 2007, 14 pts (9 males; mean age 60 years [range 48–68]) were treated with SU on the 2/1 schedule: 7 at 37.5 mg/d + G 1000 mg/m^2 + C 80 mg/m^2 (mean cycles started: 3, range 1–5); 7 at 50 mg/d + G 1000 mg/m^2 + C 80 mg/m^2 (mean cycles started: 4, range 1–6). No dose-limiting toxicities (DLTs) were observed with SU 37.5 mg/d. 2 pts receiving SU 50 mg/d experienced DLTs (1 dose-limiting neutropenia and infection, 1 neutropenia, infection and thrombocytopenia). Grade 3/4 neutropenia, thrombocytopenia and anemia occurred in 4, 3 and 2 pts receiving SU 37.5 mg/d, respectively, and in 5, 5 and 0 pts receiving SU 50 mg/d, respectively. In the 50 mg/d cohort, 3 pts achieved a partial response to treatment. No apparent drug–drug interactions were observed with SU in combination with G and C based on their systemic exposures in this study.
Conclusions: SU (37.5 mg/d) on a 2/1 schedule in combination with G (1000 mg/m^2) and C (80 mg/m^2) appears to have a favorable safety profile in pts with advanced NSCLC. Ongoing investigation will determine the safety of this combination regimen with G escalated to 1250 mg/m^2 and with SU administered on a CD schedule.

6608 POSTER

An expanded access clinical program of erlotinib in patients (pts) with advanced stage IIIb/ IV non-small-cell lung cancer (NSCLC) – an update of a single institution experience

M. Tewes[1], T. Gauler[1], P. Schuett[1], V. Sailer[1], S. Bildat[1], S. Korfee[1], S. Seeber[1], W.E.E. Eberhardt[2]. *[1]University of Duisburg-Essen, West German Cancer Centre, Essen, Germany; [2]Hospital of University of Duisburg-Essen, West German Cancer Centre, Essen, Germany*

Background: Erlotinib (Tarceva®) is a small molecule designed to target the human epidermal growth factor receptor 1 (EGF-HER1). It is designed to inhibit the tyrosine kinase activity of the EGF-HER1 signaling pathway inside the cell, which may block tumor cell growth. Erlotinib has proven activity in pretreated patients with advanced non-small-cell lung cancer (NSCLC) (F. Shepherd et al., N Engl J Med 2005; 353:123−32).
Methods: Pts with stage IIIB or IV NSCLC who have received up to two lines of standard systemic chemotherapy were planned to receive erlotinib 150 mg/day until disease progression or withdrawal. The primary end point of this EAP was to provide erlotinib to NSCLC patients and secondary to investigate best response, time to progression (TTP), overall survival and therapeutic safety in a broader pts population.
Results: 75 patients were enrolled from 01/05 to 10/05 in our department. All pts were treated with erlotinib. Pt characteristics: age: median 60 years (41−81); M/F 40/35; PS 0/1/2/3: 19/42/14/0; histopathology: adeno 42, squamous cell 17, bronchioalveolar (BAC) 8, large cell 4, others 4; smoking status: current or former/never: 14/61; prior chemotherapy line: median 2 (0−3).
At the time of the data cut-off, 1st March 2007, 68 patients had discontinued study treatment and 7 patients (9.3%) were still ongoing (non-progressive). The median time to progression is 2.8 months (95% CI: 2.0−3.8), and 20 pts have been treated for 24 weeks or longer with erlotinib. Two pts have been treated for 92 weeks. 24 patients (32%) were still alive at date of data cut-off.
Response assessment in 73 evaluable pts: PR (confirmed) 6 (8%), SD 42 (56%), PD 25 (33%), overall disease control rate (ODCR) 64%. Responses have been observed predominantly in adenocarcinoma (6).
As the most common adverse events rash I°/II°/III° (17/12/14) and diarrhea I°/II°/III° (7/5/1) were experienced. One additional patient developed nausea III° and another patient vomiting III°. No grade 4 events have been observed in the study population.
Conclusion: Erlotinib shows reproducible antitumor activity in patients with advanced stage IIIb or IV non-small-cell Lung Cancer after up to two prior chemotherapy regimens. Erlotinib was generally well tolerated, the main treatment-related adverse events were generally mild to moderate (rash and diarrhea). Selective patients experience longer survival duration over 18 months with this EGF-R inhibitor.
**Sponsored by Hoffmann-La Roche.

6609 POSTER

Vandetanib in advanced non-small-cell lung cancer: an ongoing clinical evaluation programme

H.J.M. Groen[1], P. Baas[2], S.J. Kennedy[3], P. Langmuir[4]. *[1]University Medical Center Groningen, Dept of Pulmonary Diseases, Groningen, The Netherlands; [2]The Netherlands Cancer Institute, Dept of Thoracic Oncology, Amsterdam, The Netherlands; [3]AstraZeneca, Alderley Park, Cheshire, United Kingdom; [4]AstraZeneca, Wilmington, Delaware, USA*

Vandetanib (ZACTIMA™; ZD6474) is a once-daily oral anticancer drug in phase III clinical development in a broad population of patients with advanced NSCLC. Vandetanib targets VEGFR-dependent tumour angiogenesis and EGFR- and RET-dependent tumour growth and survival. Phase I evaluation in patients with advanced solid tumours showed vandetanib was generally well tolerated at daily oral doses of $\leqslant$300 mg. Common adverse events included rash, diarrhoea and asymptomatic QTc prolongation, all of which were controlled by standard management. A